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Dear Editor:
Peritoneal dialysis is a type of renal replacement ther-
apy that uses the physical and chemical properties of the
peritoneal membrane to perform ultraﬁltration and clear-
ance processes.1–3 One complication of this procedure is
peritonitis,4,5 which is diagnosed with the presence of at least
two out of the three following criteria: a leukocyte count higher
than 100 mm−3, a corresponding clinical picture and microor-
ganisms on a Gram stain.4,5
The International Society for Peritoneal Dialysis recom-
mends management with ﬁrst-generation cephalosporins
for Gram-positive microorganisms and third-generation
cephalosporins for Gram-negative microorganisms.6
It also recommends starting treatment with third-
generation cephalosporins (ceftazidime) and ﬁrst-generation
cephalosporins (cefalotin) by the intraperitoneal route, with
permeation doses of one gram and maintenance doses of
250 mg  every 6 h; however, the response is uncertain.7
Against this background, the aim of this study was to
compare the efﬁcacy of the permeation regime and the main-
tenance regime in patients with peritonitis due to dialysis.
A cohort study was conducted in patients with end-stage
renal disease and peritonitis. The exposure group includedDOI of original article:
http://dx.doi.org/10.1016/j.nefro.2016.02.006.
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patients treated with a permeation regimen (one gram of
ceftazidime/cefalotin q 24 h); the unexposed group included
patients with a maintenance regimen (one gram initially and
250 mg of ceftazidime/cefalotin q 6 h thereafter).
Patients with a diagnosis made by cell count were included;
patients with refractory peritonitis, recurrent peritonitis or
cephalosporin allergy were excluded.
The sample (31 per group) was calculated using a percent-
age formula for 2 populations, assuming that the efﬁcacy of
ceftazidime/cefalotin was 60% in the permeation group and
35% in the maintenance group.
Their sociodemographic characteristics, concomitant dis-
eases, modality of dialysis, time on peritoneal dialysis and
time of progression of chronic kidney disease were studied.
Therapeutic efﬁcacy was established through cell counts,
using 99 cells per ﬁeld as a cut-off point, evaluated at 24, 48,
72 and 96 h.
Analysis included percentages, averages, standard devia-
tions, Student’s t-test for independent populations and the
chi-squared test.
Age and gender were similar in the permeation group and
the maintenance group: 48.06 ± 17.79 years and 55.07 ± 12.64
years (p = 0.84); male gender with 65.6% and 62.1%, respec-rreal-Ríos E, Galicia-Rodríguez L, Martínez-González L. Eﬁcacia
tazidima/cefalotina en pacientes con peritonitis por diálisis.
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Table 1 – Time in dialysis and CKD by permeation (PERM) g
Antibiotic therap
PERM 
Years in PD 21.1 (16.6) 
Years of CKD 23.5 (17.0) 
Table 2 – Efﬁcacy of permeation and maintenance by start 
Start time of
treatment
Efﬁcacya
Permeation M
Percentages
At 24 h 0.0 
At 48 h 21.9 
At 72 h 50.0 
At 96 h 65.6 
a Efﬁcacy was considered to be a cell count lower than or equal to 99
p = 1.00), diabetes mellitus (p = 0.62) and drug immunosup-
ression (p = 0.35) were similar.
In both groups there was a predominance of continuous
mbulatory peritoneal dialysis (59.4% and 69.0%, respectively;
 = 0.51). Time in dialysis (p = 0.19) and time of progression of
hronic kidney disease (p = 0.18) were similar in the groups
Table 1).
Seventy two  hours after initiation of therapy, efﬁcacy was
0.0% in the permeation group and 41.4% in the maintenance
roup; however, they were not statistically different (p = 0.50).
t 96 h, a statistical difference was found: in the perme-
tion modality 65.6% showed efﬁcacy and in the maintenance
odality 41.4% showed efﬁcacy (p = 0.05) (Table 2).
In the management of bacterial peritonitis associated with
ialysis, the antimicrobial regimens and dosage regimens
roposed in clinical practice guidelines have shown to pro-
uce ineffective results, hence the importance of this study
nalysing the prolonged stay of the antibiotic in the abdominal
avity and the decrease in the manipulation of the peritoneal
avity.8
It was ensured that the 2 groups were statistically similar
ith respect to disease history, type of dialysis, time of pro-
ression of chronic kidney disease and time in dialysis as these
ere signiﬁcant benchmarks that made comparison between
he different management regimens more  reliable.
Similarly, the same antibiotic was used in the 2 groups
s this made it possible to be certain that what was being
ompared was the number of drug administrations (one
dministration vs 4 administrations). The pathophysiological
ubstrate was the drug’s cumulative capacity in the peri-
oneum and its half-life, as well as the peritoneum’s lower
xposure to the introduction of microorganisms in each drug
dministration. To date, this matter has not received enough
8,9ttention.
Cephalosporins are ﬁrst-line antibiotics in the treatment
f peritonitis in dialysis: as they are administered by the
ntraperitoneal route, they penetrate the tissue wall and
chieve a half-life of 48–72 h. However, it will be necessary to
larify whether the efﬁcacy achieved in the permeation regi-
en  is due to the fact of exposing the peritoneum to a high
7
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 and maintenance (MAIN) group in peritonitis. Mean (SD).
MAIN t p
6.1 (12.3) 1.3 0.19
8.2 (13.0) 1.3 0.18
 of treatment in peritonitis.
p RM
enance
.0 1.00 0.0
.8 0.4 1.7
.4 0.5 1.4
.4 0.05 2.7 per ﬁeld.
dose of antibiotic, or to the fact of decreasing the events that
penetrate the peritoneal cavity and therefore the potential for
keeping from introducing germs into the cavity.6
In conclusion, the permeation regimen has a greater efﬁ-
cacy than the maintenance regimen in the management of
peritonitis secondary to peritoneal dialysis.
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Dear Editor,
Lipodystrophies (LDs) are a heterogeneous group of genetic
and acquired disorders that mainly affect women. They are
characterised by total or partial loss of subcutaneous adipose
tissue (lipoatrophy), which may be associated with accumula-
tion of fat (lipohypertrophy) in different regions of the body.
Patients with LDs have extreme insulin resistance, hyper-
glycaemia, severe hypertriglyceridaemia, low HDL levels and
fatty liver. The seriousness of these metabolic complications
is correlated with the extent of fat loss.1,2
There are 2 hereditary forms:
- Generalised lipodystrophy, which has an autosomal reces-
sive inheritance pattern and is characterised by total loss of
subcutaneous adipose tissue, and
- Congenital partial lipodystrophy, the more  common form,
which has an autosomal dominant inheritance pattern and
is linked to partial loss of adipose tissue.3
Several researchers have noted that the metabolic abnor-
malities observed are due to a failure in the functions of
regulation of fatty acid storage and release of adipose tis-
sue. There are also genes involved in the effector actions of
insulin, and in adipocyte proliferation and differentiation. Dif-
ferent candidate genes have been analysed, such as the insulin
receptor gene, the insulin receptor substrate 1 gene and the
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beta-2 adrenergic receptor gene.4 The lack of subcutaneous
adipose tissue deposits is due to the low concentration of lep-
tin. Hypoleptinaemia alters the hunger/satiety signals in the
central nervous system and causes hyperphagia. Then, caloric
excess causes fat to accumulate in the muscles and liver and
triggers severe insulin resistance, diabetes with high insulin
requirements and hypertriglyceridaemia, which creates a high
risk of pancreatitis. Patients with LDs also have fatty liver,
myocardiopathies and proteinuric nephropathies.5
A 41-year-old female patient with a diagnosis of con-
genital partial lipodystrophy, diabetes diagnosed at age 15,
being treated with insulin aspart (115 IU/day), with poor gly-
caemic control, who had bilateral proliferative retinopathy
and end-stage renal disease secondary to membranoprolifer-
ative glomerulonephritis type I (by renal punch biopsy [RPB]),
in haemodialysis three times per week since April 2012. In
addition, she had mixed dyslipidaemia being treated with
atorvastatin 20 mg/day and fenoﬁbrate 200 mg/day and HTN.
Physical examination (PE): dry weight 66.500 kg; height 170 cm;
BMI: 23.01; BP 160/70.
Her limbs looked thin, with loss of subcutaneous fat in
the buttocks, thighs and upper limbs. Hypotrophic breasts,
slight hepatomegaly, acanthosis nigricans on the neck and
hirsutism.
It was decided to place her on the waiting list for a
double kidney–pancreas transplant, considering her CKD, Giunippero A, et al. Trasplante simultáneo de rin˜ón y páncreas
;36:450–451.
in dialysis and her diabetes without insulin resistance,
